Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
AbbVie's $10B ImmunoGen deal was won by paying $7 a share over a rival bidder's offer, SEC filings show
In ImmunoGen’s months-long negotiations to sell itself, AbbVie came in relatively late but managed to seal the deal with an offer much higher than rival …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
